https://scholars.lib.ntu.edu.tw/handle/123456789/494931
標題: | Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC | 作者: | Gadgeel S Shaw A.T Barlesi F Crinò L CHIH-HSIN YANG Dingemans A.-M.C Kim D.-W De Marinis F Schulz M Liu S Gupta R Kotb A Ou S.-H.I. |
關鍵字: | alectinib; ALK positive; central nervous system; cumulative incidence rates; disease progression; non-small-cell lung cancer; phase II | 公開日期: | 2018 | 出版社: | Nature Publishing Group | 卷: | 118 | 期: | 1 | 起(迄)頁: | 38-42 | 來源出版物: | British Journal of Cancer | 摘要: | Background:We evaluated the cumulative incidence rate (CIR) of central nervous system (CNS) and non-CNS progression in alectinib-treated patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) to determine the extent to which alectinib may treat or control CNS disease.Methods:Patients with crizotinib-pretreated locally advanced or metastatic disease received alectinib 600 mg orally twice daily in two phase II trials. All patients underwent baseline imaging and regular centrally reviewed scans.Results:At 24 months, the CIR for CNS progression was lower in patients without vs with baseline CNS metastases (8.0 vs 43.9%). Patients with baseline CNS disease and prior radiotherapy had a higher CIR of CNS progression than radiotherapy-naive patients (50.5 vs 27.4%) and a lower CIR of non-CNS progression (25.8 vs 42.5%). Adverse events leading to withdrawal occurred in 5.9% and 6.7% of patients with and without baseline CNS metastases, respectively.Conclusions:This analysis indicates a potential role for alectinib in controlling and preventing CNS metastases. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85040316540&doi=10.1038%2fbjc.2017.395&partnerID=40&md5=3fb3b8c08ecfe88d5fad9c0b963da2ff https://scholars.lib.ntu.edu.tw/handle/123456789/494931 |
ISSN: | 0007-0920 | DOI: | 10.1038/bjc.2017.395 | SDG/關鍵字: | alectinib; anaplastic lymphoma kinase; alectinib; ALK protein, human; anaplastic lymphoma kinase; carbazole derivative; piperidine derivative; protein kinase inhibitor; adult; Article; brain metastasis; cancer chemotherapy; cancer incidence; cancer patient; central nervous system; central nervous system disease; controlled study; disease course; female; human; major clinical study; male; non small cell lung cancer; patient history of radiotherapy; phase 2 clinical trial; priority journal; response evaluation criteria in solid tumors; treatment duration; aged; central nervous system tumor; clinical trial; disease exacerbation; genetics; incidence; lung tumor; middle aged; non small cell lung cancer; oral drug administration; secondary; treatment outcome; young adult; Administration, Oral; Adult; Aged; Anaplastic Lymphoma Kinase; Carbazoles; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; Female; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Treatment Outcome; Young Adult |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。